NCT01362140已完成3 期
A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Amgen
- 入组人数
- 147
- 试验地点
- 1
- 主要终点
- Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period
研究概览
简要总结
The primary objective was to assess the superiority of darbepoetin alfa versus placebo on the incidence of red blood cell transfusions during the 24-week double-blind treatment period in anemic patients with low or intermediate-1 risk MDS.
详细描述
This study consists of a 3-week screening period, a 24-week double-blind treatment period, and a 48-week active treatment period and the long-term follow-up period.
An end of treatment period (EOTP) visit occurs at week 25, or 3 weeks after last dose of investigational product (IP) for participants who withdraw from the study. After entering the active treatment period, an end of active treatment period (EOATP) visit occurs at week 72 / 73, or 3 weeks after the last dose of darbepoetin alfa.
Long-term follow-up (LTFU) will occur every 26 weeks (± 4 weeks) from the EOATP visit (or EOTP visit if the participant does not enter the active treatment period) and will continue for a minimum of 3 years from the first dose of IP. Follow-up may occur through clinic visit or telephone contacts. Information on the participant's survival and progression to AML status will be collected during LTFU.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Low or intermediate-1 risk MDS patients per International Prognostic Scoring System (IPSS) at the time of randomisation, as determined by complete blood count (CBC) during screening and bone marrow examination and marrow cytogenetic analysis performed within 16 weeks prior to randomisation. Subject cannot have been rendered low or intermediate-1 risk by prior disease modifying therapy. Bone marrow slides must be available for centralized review at any time throughout the study
- •World Health Organization (WHO) classification of refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory cytopenias with multilineage dysplasia (RCMD), MDS-unclassified (MDSU), MDS with isolated del(5q) (5q- syndrome) or refractory anaemia with excess blasts-1 (RAEB-1)
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 assessed during screening
- •Haemoglobin level ≤ 10.0 g/dL as assessed by the local laboratory; sample obtained within 7 days prior to randomisation (retest during screening is acceptable)
- •Adequate transferrin saturation (Tsat) (≥ 15%) and serum ferritin (≥ 10 ng/mL) as assessed by the central laboratory during screening (supplementation and retest during screening is acceptable)
- •Adequate serum folate (≥ 4.5 nmol/L [≥ 2.0 ng/mL]) or RBC folate (≥ 317 nmol/L [≥ 140 ng/mL]) as assessed by the local laboratory during screening (supplementation and retest during screening is acceptable)
- •Adequate vitamin B12 (≥ 148 pmol/L [≥ 200 pg/mL]) as assessed by the local laboratory during screening (supplementation and retest during screening is acceptable)
- •18 years of age or older
- •Subject or subject's legally acceptable representative has provided informed consent -
排除标准
- •Previously diagnosed with intermediate-2 or high risk MDS per IPSS
- •Therapy-related or secondary MDS
- •History of acute leukemia
- •Evidence of bone marrow collagen fibrosis
- •Inherited anaemia (eg, haemoglobinopathy, thalassemia, red cell membrane defect, red cell enzyme deficiency), active hemorrhage, red cell aplasia, haemolytic anaemia
- •History of malignancies other than curatively treated non-melanoma skin or in situ carcinoma
- •History of thrombosis within 6 months prior to randomisation
- •Previous bone marrow or stem cell transplantation
- •Uncontrolled angina, uncontrolled heart failure, or uncontrolled cardiac arrhythmia as determined by the investigator at screening. Subjects with known myocardial infarction within 6 months prior to randomisation
- •Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg at screening
- •Clinically significant systemic infection or uncontrolled chronic inflammatory disease (ie, rheumatoid arthritis, inflammatory bowel disease) as determined by the investigator at screening
- •History of seizure disorder (subject with previous history of seizure disorder will be eligible for the study if he/she had no evidence of seizure activity within 5 years of randomisation and is currently free of antiseizure medication)
- •Previous or ongoing use of erythropoiesis-stimulating agent (ESA) therapy, eg, recombinant human erythropoietin (rHuEpo), darbepoetin alfa
- •High transfusion demand: receiving a total of ≥ 4 units of RBC transfusion during either of 2 consecutive 8-week periods (ie, days -113 to -57 or days -56 to 0) prior to randomisation
- •Received any RBC transfusion within 14 days prior to randomisation
- •Received cytotoxic chemotherapy for any oncologic indication or planning to receive cytotoxic chemotherapy during the double-blind treatment period of the study
- •Received biologic response modifiers (eg, thalidomide, lenalidomide, arsenic trioxide, azacitidine, decitabine) to treat MDS or planning to receive biologic response modifiers during the double-blind treatment period of the study
- •Received myeloablative or craniospinal radiation or planning to receive myeloablative or craniospinal radiation during the double-blind treatment period of the study
- •Received granulocyte colony stimulating factor (G-CSF) therapy within 30 days prior to randomization or planning to receive G-CSF therapy during the double-blind treatment period of the study (temporary use of G-CSF for neutropenia with fever and/or infection is acceptable)
- •Abnormal renal function (serum creatinine level > 2 times the upper limit of the respective normal range [ULN]) as assessed by the central laboratory at screening
- •Abnormal liver function (total bilirubin > 2 times, alanine aminotransferase [ALT] or aspartate aminotransferase [AST] > 3 times ULN) as assessed by the central laboratory at screening. (Subjects with abnormal bilirubin at screening due to documented Gilbert's Disease are eligible if all other criteria are met.)
- •Serum endogenous erythropoetin (EPO) level > 500 mU/mL as assessed by the central laboratory at screening
- •Known seropositivity for human immunodeficiency virus (HIV) or diagnosis of acquired Immunodeficiency syndrome (AIDS), positive for hepatitis B surface antigen, or seropositive for hepatitis C virus
- •Subjects with active ethanol abuse, as judged by the investigator
- •Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)
- •Female subject is not willing to use highly effective contraception during treatment and for at least 1 month after the end of treatment
- •Female subject is pregnant or planning to become pregnant within 1 month after the end of treatment
- •Subject has known sensitivity to any of the products to be administered during dosing
- •Subject has previously been randomised into this study
- •Subject will not be available for protocol-required study visits, to the best of the subject and investigator's knowledge
- •Subject has any kind of disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or to comply with all required study procedures
- •Confirmed history of neutralising antibody activity to rHuEpo or darbepoetin alfa
研究组 & 干预措施
Darbepoetin alfa
Experimental
Participants received darbepoetin alfa 500 µg every three weeks (Q3W) for 24 weeks in the double-blind treatment period, and continued to receive darbepoetin alfa 500 µg Q3W during the active treatment period for an additional 48 weeks.
干预措施: Darbepoetin alfa (Drug)
Placebo
Placebo Comparator
Participants received placebo subcutaneous injection every 3 weeks (Q3W) for 24 weeks during the double-blind treatment period. From week 25 participants received darbepoetin alfa 500 µg Q3W during the active treatment period for 48 weeks.
干预措施: Placebo (Drug)
结局指标
主要结局
Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period
时间窗: Week 5 to Week 25
次要结局
- Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)(Baseline, and weeks 13 and 25)
- Percentage of Participants With a Clinically Meaningful Improvement in Fatigue(Baseline to week 24)
- Percentage of Participants Who Achieved an Erythroid Response Based on International Working Group (IWG) 2006 Criteria in the Double-blind Treatment Period(Up to 24 weeks)
- Number of Participants With Adverse Events(From first dose of study drug until the end of the double-blind treatment period; 24 weeks.)
- Number of Participants With Malignancies Other Than AML, Basal Cell Carcinoma, or Squamous Cell Carcinoma of the Skin(Up to 24 weeks)
- Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa(Baseline and end of double-blind treatment period (24 weeks))
- Number of Participants With Disease Progression to Acute Myeloid Leukemia (AML)(24 weeks)
- Change From Baseline in EuroQol-5D (EQ-5D) Visual Analog Scale (VAS)(Baseline, and weeks 13 and 25)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Darbepoetin Alfa for the Treatment of Anemia of CancerCancerAnemiaNCT00091858Amgen1,000
已完成
3 期
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle ChemotherapyNon-Myeloid MalignanciesAnemiaNCT00110955Amgen391
已完成
3 期
A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing ChemotherapyAnemiaNCT03776032Amgen320
已完成
3 期
Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney DiseaseChronic Kidney DiseaseAnemiaNCT00925587Amgen358
已完成
3 期
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney DiseaseAnemiaKidney DiseaseNCT00121602Amgen446